Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity

Journal of Nuclear Medicine

Volumn 38, Issue 5, 1997, Pages 797-802

  Borght, Thierry Vander ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; emission computed tomography; fluorine 18 FDG; Lewy body disease; Parkinson's disease

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; STEREOTAXIC TECHNIQUES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030979769     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Lieberman A, Dziatolowski M, Kupersmith M, et al. Dementia in Parkinson disease. Ann Neural 1979:6:355-359.
2. Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet 1984;2:1262-1265.
3. Hakim AM, Mathieson G. Dementia in Parkinson disease: a neuropathologic study. Neurology 1979;29:1209-1214.
4. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: -evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neural 1981:10:122-126.
5. Whitehouse PJ, Hedreen JC, White CL, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neural 1983; 13:243-248.
6. Kühl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization -determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neural 1984:15:419-424.
7. Peppard RF, Martin WR, Carr GD, et al. Cerebral glucose metabolism in Parkinson's -disease with and without dementia. Arch Neural 1992;49:1262-1268.
8. Schapiro MB, Pietrini P, Grady CL, et al. Reductions in parietal and temporal cerebral -metabolic rates for glucose are not specific for Alzheimer's disease. .7 Neural Neurosurg Psychiatry 1993;56:859-864.
9. Pizzolato G, Dam M, Borsato N, et al. Technetium-99m-HMPAO SPECT in -Parkinson's disease. J Cereb Blood Flow Metab 1988;8:S101-S108.
10. Spampinato U, Habert MO, Mas JL, et al. Technetium-99m-HMPAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. J Neural Neurosurg Psychiatry 1991;54:787-792.
11. Mann DM, Yates PO. Pathological basis for neurotransmitter changes in Parkinson's -disease. Neuropathol Appl Neurobiol 1983;9:3-19.
12. Jellinger K, Riederer P. Dementia in Parkinson's disease, and (pre)senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. Adv Neural 1984;40:199-210.
13. de la Monte SM, Wells SE, Hedley-Whyte T, Growdon JH. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Ann Neural 1989;26:309-320.
14. Vermersch P, Delacourte A, Javoy-Agid F, Hauw JJ, Agid Y. Dementia in Parkinson's -disease: biochemical evidence for cortical involvement using the immunodetection of -abnormal Tau proteins. Ann Neural 1993;33:445-450.
15. Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neural Sei 1983;59:277-289.
16. Marder K, Maestre G, Cote L, et al. The apolipoprotein epsilon 4 allele in Parkinson's -disease with and without dementia. Neurology 1994;44:1330-1331.
17. Lewy FH. Paralysis agitans: I. Pathologische anatomie. In: Lewandowsky M, ed. Handbuch der Neurologie HI. Berlin: Springer Verlag; 1912:920-933.
18. Kosaka K, Mehraein P. Dementia-Parkinsonism syndrome with numerous Lewy bodies and senile plaques in cerebral cortex. Arch Psychiatr Nervenkr 1979;226:241250.
19. Gibb WR, Mountjoy CQ, Mann DM, Lees AJ. A pathological study of the association between Lewy body disease and Alzheimer's disease. J Neural Neurosurg Psychiatry 1989;52:701-708.
20. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neural 1993;50:140-148.
21. Knopman DS, Mastri AR, Frey WHd, Sung JH, Rustan T. Dementia lacking distinctive histologie features: a common non-Alzheimer degenerative dementia. Neurology 1990:40:251-256.
22. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kühl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluo-rine-18-FDG PET. J Nucl Med 1995;36:1238-1248.
23. Wechsler D. Wechsler adult intelligence scale, revised. New York: Psychological Corporation; 1981.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189198.
25. Gelb DJ, St Laurent RT. Alternative calculation of the global clinical dementia rating. Alzheimer Dis Assoc Disord 1993;7:202-211.
26. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114:797- 811.
27. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kühl DE, Sima AAF. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996:47:462-466.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
29. Kaplan E, Goodglass H, Weintraub S. In: The Boston naming test, eds., 2nd ed. Boston: Kaplan, Goodglass; 1978.
30. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
31. Hutchins GD, Holden JE, Koeppe RA, Halama JR, Galley SJ, Nickles RJ. Alternative approach to single-scan estimation of cerebral glucose metabolic rate using glucose analogs, with particular application to ischemia. J Cereb Blood Flow Metab 1984;4: 35-40.
32. Minoshima S, Koeppe RA, Frey KA, Kühl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:15281537.
33. Minoshima S, Frey KA, Foster NL, Kühl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995; 19:541-547.
34. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988.
35. Minoshima S, Foster NL, Kühl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet 1994;344:895.
36. Sasaki M, Ichiya Y, Hosokawa S, et al. Regional cerebral glucose metabolism in
37. patients with Parkinson's disease with or without dementia. Ann Nuklearmediiin 1992;6:241-246.
38. 18F scan in Alzheimer's disease and multi-infarct dementia. Arch Neural 1983;40:711-714.
39. Kühl DE, Metter EJ, Benson DF, et al. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinson's dementia. J Cereb Blood How Melab 1985;5:S169 S170.
40. Liu RS, Lin KN, Wang SJ, et al. Cognition and y"nlTc-HMPAO SPECT in Parkinson's -disease. Nucl Med Commun 1992:13:744-748.
41. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ. Cortical glucose -metabolism in Parkinson's disease without dementia. Neurobiol Aging 1994:15:329 335.
42. Rougemont D, Baron JC, Collard P, Bustany P, Comar D, Agid Y. Eocal cerebral -glucose utilisation in treated and untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1984;47:824-830.
43. Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson's -disease. Brain 1978;101:661-67I.
44. Bodis-Wollner I, Yahr MD, Mylin E, Thornton J. Dopaminergic deficiency and -delayed visual evoked potentials in humans. Ann Neurol 1982;11:478-483.
45. Ikeda H, Head GM, Ellis CJ. Electrophysiological signs of retinal dopamine deficiency -in recently diagnosed Parkinson's disease and a follow up study. Vision Res 1994;34:2629-2638.
46. Nguyen-Legros .1. llarnois (.', Di Paolo I, Simon A. The retinal dopamine system in Parkinson's disease. Clin Vision Sei 1993:8:1 12.
47. O'Mahony D, Rowan M. Fcely .1, O'Neill [), Walsh JB. C'oaklcy I). Parkmson's dementia and Al/heimcr's dementia: an evoked potential comparison, (ieronlologv 1993:39:228 240.
48. Braak H, Braak H. Neuropathological stageing of Alzheimer-related changes. Ada Neuropatlmt (Berl) 1991:82:239-259.
49. Jagust W.I, Eberling JL, Richardson BC. et al. The cortical topography of temporal -lobe hypometabolism in early Alzheimer's disease. Brain Res 1993:629:189 19s.
50. Ince P. Irving I). MacArthur F. Perry RH. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Al/hcimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients../ Neural Sei 1991; 106:142 152.
51. Hansen LA, Masliah K, Quijada-Fawcett s, Rexin D. Entorhinal neurofibrillary tangles -in Alzheimer disease with Lewy bodies. Neurosci Lett 1991:129:269 272.
52. Lippa CF, Smith TW, Swearer JM. Alzheimer's disease and Lewy body disease: a -comparative clinicopathological study. Ann Neural 1994:35:81 -88.
53. Wakabayashi K, Honer WO, Masliah F.. Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Res 1994;667:24-32.
54. Katzman R, Galasko D, Saitoh T, Thal LJ, Hansen L. Genetic evidence that the Lewy -body variant is indeed a phenotypie variant of Alzheimer's disease. Brain Cogn 1995:28:259-265.